Personalized medicine for depression: Can we match patients with treatments?

American Journal of Psychiatry

Volumn 167, Issue 12, 2010, Pages 1445-1455

  Simon, Gregory E ^a   Perlis, Roy H ^b  

^a GROUP HEALTH RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BIOLOGICAL MARKER; CITALOPRAM; FLUOXETINE; IMIPRAMINE; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AVOIDANT PERSONALITY DISORDER; BEHAVIOR THERAPY; BORDERLINE STATE; CLINICAL PRACTICE; COGNITIVE THERAPY; DEPRESSION; DRUG CHOICE; GENETIC VARIABILITY; HUMAN; INSOMNIA; MALADJUSTMENT; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MODEL; OBSESSIVE COMPULSIVE DISORDER; PATIENT SELECTION; PERSONALITY DISORDER; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; SUICIDAL IDEATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DECISION SUPPORT TECHNIQUES; DEPRESSION; HUMANS; INDIVIDUALIZED MEDICINE; PSYCHOTHERAPY;

EID: 78649726626     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2010.09111680     Document Type: Review

References (87)

1. Agency for Health Care Policy and Research Depression Guideline Panel: Clinical Practice Guideline Number 5: Depression in Primary Care (AHCPR Publication No 93-0550). Rockville, Md, US Department of Health and Human Services, 1993
2. Parikh S, Lam R; CANMAT Depression Work Group: Clinical guidelines for the treatment of depressive disorders, I: definitions, prevalence, and health burden. Can J Psychiatry 2001; 46(suppl 1):13S-20S
3. American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157:s1-s45
4. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN: Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008; 149:734-750
5. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373:746-758
6. Simon G: Choosing a first-line antidepressant: equal on average does not mean equal for everyone. JAMA 2001; 286:3003-3004
7. Kravitz RL, Duan N, Braslow J: Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 2004; 82:661-687 (Pubitemid 40143102)
8. Rush A, Trivedi M, Wisniewski S, Stewart J, Nierenberg A, Thase M, Ritz L, Biggs M, Warden D, Luther J, Shores-Wilson K, Niederehe G, Fava M; STAR*D Study Team: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354:1231-1242
9. Trivedi M, Fava M, Wisniewski S, Thase M, Quitkin F, Warden D, Ritz L, Nierenberg A, Lebowitz B, Biggs M, Luther J, Shores-Wilson K, Rush A; STAR*D Study Team: Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243-1252
10. Thase M, Friedman E, Biggs M, Wisniewski S, Trivedi M, Luther J, Fava M, Nierenberg A, McGrath P, Warden D, Niederehe G, Hollon S, Rush A: Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007; 164:739-752
11. Simon G, Von Korff M, Rutter C, Peterson D: Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians. Arch Gen Psychiatry 2001; 58:395-401 (Pubitemid 32299536)
12. National Committee for Quality Assurance: The State of Health Care Quality 2007. Washington, DC, National Committee for Quality Assurance, 2007
13. Papakostas GI, Fava M: Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues Clin Neurosci 2008; 10:439-451
14. Baron R, Kenny DA: The moderator-mediator distinction in social psychological research: conceptual, strategic and statistical considerations. J Pers Soc Psychol 1986; 51:1173-1182
15. Kraemer H, Wilson T, Fairburn C, Agras W: Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 2002; 59:877-883
16. Kraemer HC, Frank E, Kupfer DJ: Moderators of treatment outcomes: clinical, research, and policy importance. JAMA 2006; 296:1286-1289 (Pubitemid 44394901)
17. Joyce P, McKenzie J, Carter J, Rae A, Luty S, Frampton C, Mulder R: Temperament, character, and personality disorders as predictors of response to interpersonal psychotherapy and cognitive-behavioural therapy for depression. Br J Psychiatry 2007; 190:503-508 (Pubitemid 46868834)
18. Bellino S, Zizza M, Rinaldi C, Bogetto F: Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Can J Psychiatry 2007; 52:718-725
19. Rush A, Wisniewski S, Warden D, Luther J, Davis L, Fava M, Nierenberg A, Trivedi M: Selecting among second-step antidepressant medication monotherapies: Are clinical, demographic, or first-step treatment results informative? Arch Gen Psychiatry 2008; 65:870-880
20. Trivedi M, Rush A, Wisniewski S, Nierenberg A, Warden D, Ritz L, Norquist G, Howland R, Lebowitz B, McGrath P, Shores-Wilson K, Biggs M, Balasubramani G, Fava M; STAR*D Study Team: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28-40
21. Khan A, Leventhal R, Khan S, Brown W: Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002; 22:40-45
22. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J: Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303:47-53
23. Thase ME, Buysse DJ, Frank E, Cherry CR, Cornes CL, Mallinger AG, Kupfer DJ: Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEG sleep profiles. Am J Psychiatry 1997; 154:502-509 (Pubitemid 27147603)
24. Thase ME, Dube S, Bowler K, Howland RH, Myers JE, Friedman E, Jarrett DB: Hypothalamic-pituitary-adrenocortical activity and response to cognitive behavior therapy in unmedicated, hospitalized depressed patients. Am J Psychiatry 1996; 153:886-891
25. Thase ME, Simons AD, Reynolds CF 3rd: Psychobiological correlates of poor response to cognitive behavior therapy: potential indications for antidepressant pharmacotherapy. Psychopharmacol Bull 1993; 29:293-301
26. DeRubeis R, Gelfand L, Tang T, Simons A: Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. Am J Psychiatry 1999; 156:1007-1013
27. DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, O'Reardon JP, Lovett ML, Gladis MM, Brown LL, Gallop R: Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005; 62:409-416
28. Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, Gallop R, McGlinchey JB, Markley DK, Gollan JK, Atkins DC, Dunner DL, Jacobson NS: Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol 2006; 74:658-670
29. Fournier JC, DeRubeis RJ, Shelton RC, Gallop R, Amsterdam JD, Hollon SD: Antidepressant medications v cognitive therapy in people with depression with or without personality disorder. Br J Psychiatry 2008; 192:124-129 (Pubitemid 351269646)
30. Fournier JC, DeRubeis RJ, Shelton RC, Hollon SD, Amsterdam JD, Gallop R: Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. J Consult Clin Psychol 2009; 77:775-787
31. Bagby RM, Quilty LC, Segal ZV, McBride CC, Kennedy SH, Costa PT: Personality and differential treatment response in major depression: a randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy. Can J Psychiatry 2008; 53:361-370
32. Maddux RE, Riso LP, Klein DN, Markowitz JC, Rothbaum BO, Arnow BA, Manber R, Blalock JA, Keitner GI, Thase ME: Select comorbid personality disorders and the treatment of chronic depression with nefazodone, targeted psychotherapy, or their combination. J Affect Disord 2009; 117:174-179
33. Nemeroff C, Heim C, Thase M, Klein D, Rush A, Schatzberg A, Ninan P, McCullough J, Weiss P, Dunner D, Rothbaum B, Kornstein S, Keitner G, Keller M: Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 2003; 100:14293-14296
34. Kocsis JH, Leon AC, Markowitz JC, Manber R, Arnow B, Klein DN, Thase ME: Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. J Clin Psychiatry 2009; 70:354-361
35. Bellino S, Zizza M, Rinaldi C, Bogetto F: Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Can J Psychiatry 2006; 51:453-460 (Pubitemid 44065747)
36. Kool S, Dekker J, Duijens I, de Jonghe F, Puite B: Efficacy of combined therapy and pharmacotherapy for depressed patients with or without personality disorders. Harv Rev Psychiatry 2003; 11:133-141 (Pubitemid 36765071)
37. McGrath P, Stewart J, Harrison W, Ocepek-Welikson K, Rabkin J, Nunes E, Wagner S, Tricamo E, Quitkin F, Klein D: Predictive value of symptoms of atypical depression for differential drug treatment outcome. J Clin Psychopharmacol 1992; 12:197-202
38. McGrath P, Stewart J, Janal M, Petkova E, Quitkin F, Klein D: A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry 2000; 157:344-350 (Pubitemid 30145918)
39. Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, Fava M: Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry 2008; 69:1287-1292
40. Zetin M, Hoepner C, Bjornson L: Rational antidepressant selection: applying evidence-based medicine to complex real-world patients. Psychopharmacol Bull 2006; 39:38-104
41. Remillard A, Blackshaw S, Dangor A: Differential responses to a single antidepressant in recurrent episodes of major depression. Hosp Community Psychiatry 1994; 45:359-361 (Pubitemid 24112971)
42. Cobbin D, Requin-Blow B, Williams L, Williams W: Urinary MHPG levels and tricyclic antidepressant drug selection: a preliminary communication on improved drug selection in clinical practice. Arch Gen Psychiatry 1979; 36:1111-1115 (Pubitemid 10118067)
43. Janicak P, Davis J, Chan C, Altman E, Hedeker D: Failure of urinary MHPG levels to predict depression treatment response in patients with unipolar depression. Am J Psychiatry 1986; 143:1398-1402
44. Perlis RH, Iosifescu DV, Renshaw PF: Biological predictors of treatment response in affective illness. Psychiatr Clin North Am 2003; 26:323-344
45. Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP: Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 2009; 65:785-791
46. Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Knoue K, Suzuki T, Nemeroff C: Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004; 161:1575-1580
47. Hong C, Chen T, Yu Y, Tsai S: Response to fluoxetine and serotonin 1A (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006; 6:27-33 (Pubitemid 43118308)
48. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ: Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 2007; 164:1181-1188
49. Lekman M, Laje G, Charney D, Rush A, Wilson A, Sorant A, Lipsky R, Wisniewski S, Manji H, McMahon F, Paddock S: The FKBP5-gene in depression and treatment response: an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) cohort. Biol Psychiatry 2008; 63:1103-1110
50. Yoshida K, Higuchi H, Takahashi H, Kamata M, Sato K, Inoue K, Suzuki T, Itoh K, Ozaki N: Influence of the tyrosine hydroxylase Val81MET polymorphism and catechol-O-methyltransferase Val158MET polymorphism on the antidepressant effect of milnacipran. Hum Psychopharmacol 2008; 23:121-128
51. Yu Y, Tsai L, Liou Y, Hong C, Chen T: Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol 2006; 16:498-503
52. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL, Rogers GR, Kennedy MA: Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 2003; 6:339-346
53. Kraft J, Slager S, McGrath P, Hamilton S: Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 2005; 58:374-381
54. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, Menke A, Bondy B, Rupprecht R, Domschke K, Baune BT, Arolt V, Rush AJ, Holsboer F, Muller-Myhsok B: A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009; 66:966-975
55. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB: The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004; 174:525-529
56. Szegedi A, Rujescu D, Tadic A, Muller MJ, Kohnen R, Stassen HH, Dahmen N: The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 2005; 5:49-53
57. Tadic A, Muller M, Rujescu D, Kohnen R, Stassen H, Dahmen N, Szegedi A: The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet 2007; 144:325-331
58. Tadic A, Rujescu D, Muller MJ, Kohnen R, Stassen HH, Dahmen N, Szegedi A: A monoamine oxidase B gene variant and shortterm antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1370-1377
59. A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. J Clin Psychopharmacol 2008; 28:518-524
60. Kim H, Lim S, Kim S, Kim J, Chang Y, Carroll B, Kim D: Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA 2006; 296:1609-1618
61. Yoshida K, Higuchi H, Kamata M, Takahashi H, Inoue K, Suzuki T, Itoh K, Ozaki N: The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol 2007; 21:650-656
62. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Zagar T, Czerski PM, Jerman B, Larsen ER, Schulze TG, Zobel A, Cohen-Woods S, Pirlo K, Butler AW, Muglia P, Barnes MR, Lathrop M, Farmer A, Breen G, Aitchison KJ, Craig I, Lewis CM, McGuffin P: Genomewide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010; 167:555-564
63. Perlis R, Mischoulon D, Smoller J, Wan Y, Lamon-Fava S, Lin K, Rosenbaum J, Fava M: Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003; 54:879-883
64. Bishop JR, Moline J, Ellingrod VL, Schultz SK, Clayton AH: Serotonin 2A-1438 G/A and G-protein b eta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006; 31:2281-2288
65. Perlis RH, Laje G, Smoller JW, Fava M, Rush AJ, McMahon FJ: Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology 2009; 34:1819-1828
66. Perlis R, Purcell S, Fava M, Fagerness J, Rush A, Trivedi M, Smoller J: Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007; 64:689-697
67. Smits K, Smits L, Peeters F, Schouten J, Janssen R, Smeets H, van Os J, Prins M: Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 2007; 22:137-143
68. Hu X, Rush A, Charney D, Wilson A, Sorant A, Papanicolaou G, Fava M, Trivedi M, Wisniewski S, Laje G, Paddock S, McMahon F, Manji H, Lipsky R: Association between a functional serotonin transporter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007; 64:783-792
69. Laje G, Paddock S, Manji H, Rush A, Wilson F, Charney D, McMahon F: Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007; 164:1460-1461
70. Murphy G, Kremer C, Rodrigues H, Schatzberg A: Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160:1830-1835
71. Barber JP, Muenz LR: The role of avoidance and obsessiveness in matching patients to cognitive and interpersonal psychotherapy: empirical findings from the treatment for depression collaborative research program. J Consult Clin Psychol 1996; 64:951-958
72. McBride C, Atkinson L, Quilty L, Bagby R: Attachment as moderator of treatment outcome in major depression: a randomized control trial of interpersonal psychotherapy versus cognitive behavior therapy. J Consult Clin Psychol 2006; 74:1041-1054
73. Goldstein DB: Common genetic variation and human traits. N Engl J Med 2009; 360:1696-1698
74. Hotopf M, Churchill R, Lewis G: Pragmatic randomised controlled trials in psychiatry. Br J Psychiatry 1999; 175:217-223
75. Burke W, Psaty B: Personalized medicine in the era of genomics. JAMA 2007; 298:1682-1684
76. Schelleman H, Stricker B, De Boer A, Kroon A, Verschuren M, Van Dujin C, Psaty B, Ohio K: Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 2004; 64:1801-1816
77. Nierenberg AA, Feinstein AR: How to evaluate a diagnostic marker test: lessons from the rise and fall of dexamethasone suppression test. JAMA 1988; 259:1699-1702
78. Ransohoff DF, Feinstein AR: Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978; 299:926-930
79. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG: Replication validity of genetic association studies. Nat Genet 2001; 29:306-309
80. Perlis RH, Patrick A, Smoller JW, Wang PS: When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology 2009; 34:2227-2236
81. Perlis RH, Ganz DA, Avorn J, Schneeweiss S, Glynn RJ, Smoller JW, Wang PS: Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol 2005; 25:427-434
82. Braff DL, Freedman R: Clinically responsible genetic testing in neuropsychiatric patients: a bridge too far and too soon. Am J Psychiatry 2008; 165:952-955
83. Perlis RH: Cytochrome P450 genotyping and antidepressants. BMJ 2007; 334:759
84. Gilbody S, Bower P, Fletcher J, Richards D, Sutton AJ: Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med 2006; 166:2314-2321
85. Gilbody S, Whitty P, Grimshaw J, Thomas R: Educational and organizational interventions to improve the management of depression in primary care: a systematic review. JAMA 2003; 289:3145-3151
86. Young A, Klap R, Sherbourne C, Wells K: The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry 2001; 58:55-61 (Pubitemid 32057765)
87. Simon G, Ludman E, Tutty S, Operskalski B, Von Korff M: Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment: a randomized trial. JAMA 2004; 292:935-942